Neurocrine Biosciences, Inc. (NBIX) P/E Ratio History
UndervaluedTrading at 33.9x vs 5Y avg 102.2x · 30th percentile · Below historical baseline · Data 1996–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a price-to-earnings ratio of 33.9x, with a stock price of $158.29 and trailing twelve-month earnings per share of $6.47.
The current P/E is 67% below its 5-year average of 102.2x. Over the past five years, NBIX's P/E has ranged from a low of 20.3x to a high of 861.9x, placing the current valuation at the 30th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, NBIX trades at a 53% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 14.49 (P/E divided by 42% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, NBIX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NBIX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NBIX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NBIX P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66 | +817%Best | |
| $4B | 9.4 | - | +68% | |
| $7B | 10.2 | - | +264% | |
| $7B | 31.5 | - | -34% | |
| $2B | 9.6 | 0.06Best | +40% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NBIX Historical P/E Data (1996–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $131.74 | $6.49 | 20.3x | -87% |
| FY2025 Q4 | Dec 31 2025 | $141.83 | $4.66 | 30.4x | -81% |
| FY2025 Q3 | - | $140.38 | $4.18 | 33.6x | -79% |
| FY2025 Q2 | Jun 30 2025 | $125.69 | $3.38 | 37.2x | -77% |
| FY2025 Q1 | Mar 31 2025 | $110.60 | $2.95 | 37.5x | -77% |
| FY2024 Q4 | - | $136.50 | $3.29 | 41.5x | -74% |
| FY2024 Q3 | Sep 30 2024 | $115.22 | $3.73 | 30.9x | -81% |
| FY2024 Q2 | Jun 30 2024 | $137.67 | $3.31 | 41.6x | -74% |
| FY2024 Q1 | Mar 31 2024 | $137.92 | $3.63 | 38.0x | -76% |
| FY2023 Q4 | Dec 31 2023 | $131.76 | $2.42 | 54.4x | -66% |
| FY2023 Q3 | Sep 30 2023 | $112.50 | $1.86 | 60.5x | -62% |
| FY2023 Q2 | Jun 30 2023 | $94.30 | $1.73 | 54.5x | -66% |
| FY2023 Q1 | Mar 31 2023 | $101.22 | $0.60 | 168.7x | +5% |
| FY2022 Q4 | Dec 31 2022 | $119.44 | $1.53 | 78.1x | -51% |
| FY2022 Q3 | Sep 30 2022 | $106.21 | $0.57 | 185.3x | +16% |
| FY2022 Q2 | - | $97.48 | $0.11 | 861.9x | +438% |
| FY2022 Q1 | - | $93.75 | $0.72 | 129.7x | -19% |
| FY2021 Q4 | Dec 31 2021 | $85.17 | $0.91 | 93.3x | -42% |
| FY2021 Q3 | - | $95.91 | $4.57 | 21.0x | -87% |
| FY2021 Q2 | Jun 30 2021 | $97.32 | $3.72 | 26.2x | -84% |
| FY2021 Q1 | Mar 31 2021 | $97.25 | $4.10 | 23.7x | -85% |
| FY2020 Q4 | - | $95.85 | $4.16 | 23.0x | -86% |
| FY2020 Q3 | Sep 30 2020 | $96.16 | $0.93 | 103.4x | -35% |
| FY2020 Q2 | - | $122.00 | $2.11 | 57.8x | -64% |
| FY2020 Q1 | - | $86.55 | $1.84 | 47.0x | -71% |
| FY2019 Q4 | - | $107.49 | $0.33 | 325.7x | +103% |
| FY2019 Q3 | Sep 30 2019 | $90.11 | $0.17 | 530.1x | +231% |
| FY2019 Q2 | Jun 30 2019 | $84.43 | $0.13 | 649.5x | +305% |
| FY2018 Q4 | Dec 31 2018 | $71.41 | $0.17 | 409.5x | +155% |
| FY2018 Q3 | Sep 30 2018 | $122.95 | $0.06 | 2091.0x | +1204% |
| FY2012 Q4 | Dec 31 2012 | $7.48 | $0.07 | 103.9x | -35% |
| FY2012 Q2 | Jun 30 2012 | $7.89 | $0.56 | 14.1x | -91% |
| FY2012 Q1 | Mar 31 2012 | $7.97 | $0.60 | 13.2x | -92% |
| FY2011 Q4 | Dec 31 2011 | $8.50 | $0.67 | 12.7x | -92% |
| FY2011 Q3 | Sep 30 2011 | $5.98 | $0.69 | 8.6x | -95% |
| FY2011 Q2 | - | $8.05 | $0.19 | 42.0x | -74% |
| FY2011 Q1 | - | $7.59 | $0.06 | 121.4x | -24% |
| FY1997 Q4 | Dec 31 1997 | $7.88 | $0.28 | 28.6x | -82% |
| FY1997 Q3 | - | $9.56 | $0.53 | 18.2x | -89% |
| FY1997 Q2 | Jun 30 1997 | $9.00 | $0.47 | 19.3x | -88% |
| FY1997 Q1 | Mar 31 1997 | $9.00 | $0.57 | 15.8x | -90% |
| FY1996 Q4 | - | $10.00 | $0.34 | 29.4x | -82% |
Average P/E for displayed period: 160.3x
Full Stock Analysis
Deep dive into NBIX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBIX — Frequently Asked Questions
Quick answers to the most common questions about buying NBIX stock.
What is NBIX's P/E ratio?
Neurocrine Biosciences, Inc. (NBIX) trailing twelve-month P/E ratio is 33.9x, based on TTM diluted EPS of $6.47. The 5-year average P/E is 102.2x and the historical range spans 20.3x to 861.9x.
Is NBIX stock overvalued or undervalued?
NBIX trades at 33.9x P/E, below its 5-year average of 102.2x. At the 30th percentile of its historical range (20.3x–861.9x), the stock is priced at a discount to its own history.
Is NBIX stock expensive?
No, NBIX is not expensive on a historical basis. The current P/E of 33.9x is below the 5-year average of 102.2x and sits at the 30th percentile of its valuation range.
What is NBIX's historical P/E range?
Over the past 5 years, NBIX's P/E ratio has ranged from 20.3x to 861.9x, with a median of 41.6x and an average of 102.2x. The current P/E of 33.9x places the stock at the 30th percentile of this range. Full historical data spans 1996–2026.
How does NBIX's P/E compare to the S&P 500?
NBIX trades at 33.9x P/E versus the S&P 500 median of 24.4x. The 39% premium to the market typically reflects higher expected earnings growth or quality.
How does NBIX's valuation compare to Healthcare peers?
Neurocrine Biosciences, Inc. P/E of 33.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NBIX's PEG ratio?
NBIX PEG ratio is 14.49, based on a P/E of 33.9x and EPS growth of 41.9%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is NBIX's earnings yield?
NBIX earnings yield is 2.95%, the inverse of its 33.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.